Novel Long-Acting Antipsychotic Prodrug for Schizophrenia with Dr. Sam Clark Terran Biosciences

Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments.  Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s."  "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia."  #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Download the transcript here